Skip to main content

Trade-Ideas LLC identified




) as a strong and under the radar candidate. In addition to specific proprietary factors, Trade-Ideas identified PerkinElmer as such a stock due to the following factors:

  • PKI has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $44.9 million.
  • PKI has traded 52.16420000000000101181285572238266468048095703125 options contracts today.
  • PKI is making at least a new 3-day high.
  • PKI has a PE ratio of 34.
  • PKI is mentioned 1.13 times per day on StockTwits.
  • PKI has not yet been mentioned on StockTwits today.
  • PKI is currently in the upper 20% of its 1-year range.
  • PKI is in the upper 35% of its 20-day range.
  • PKI is in the upper 45% of its 5-day range.
  • PKI is currently trading above yesterday's high.

'Strong and Under the Radar' stocks tend to be worthwhile stocks to watch for a variety of factors including historical back testing and price action. Market technicians refer to such stocks as being in an accumulation phase before a mark-up and peak. Traders and hedge funds have frequently found that these types of stocks continue to build a solid price base and then ultimately spike higher and peak when others 'discover' how good the stock is performing. By leveraging the social discovery aspect of StockTwits we are highlighting stocks that don't currently receive much attention from retail investors, but we suspect may soon garner more attention.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in PKI with the Ticky from Trade-Ideas. See the FREE profile for PKI NOW at Trade-Ideas

More details on PKI:

PerkinElmer Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, and laboratory services markets worldwide. The company operates through two segments, Human Health and Environmental Health. The stock currently has a dividend yield of 0.5%. PKI has a PE ratio of 34. Currently there are 12 analysts that rate PerkinElmer a buy, no analysts rate it a sell, and 4 rate it a hold.

The average volume for PerkinElmer has been 694,300 shares per day over the past 30 days. PerkinElmer has a market cap of $5.9 billion and is part of the health care sector and health services industry. The stock has a beta of 0.61 and a short float of 3% with 3.18 days to cover. Shares are up 20.1% year-to-date as of the close of trading on Tuesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.


TheStreet Quant Ratings

rates PerkinElmer as a


. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, solid stock price performance and increase in net income. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity.

Highlights from the ratings report include:

  • PKI's revenue growth has slightly outpaced the industry average of 5.2%. Since the same quarter one year prior, revenues slightly increased by 3.8%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
  • The current debt-to-equity ratio, 0.50, is low and is below the industry average, implying that there has been successful management of debt levels. Along with the favorable debt-to-equity ratio, the company maintains an adequate quick ratio of 1.10, which illustrates the ability to avoid short-term cash problems.
  • Looking at where the stock is today compared to one year ago, we find that it is not only higher, but it has also clearly outperformed the rise in the S&P 500 over the same period. Although other factors naturally played a role, the company's strong earnings growth was key. Turning our attention to the future direction of the stock, it goes without saying that even the best stocks can fall in an overall down market. However, in any other environment, this stock still has good upside potential despite the fact that it has already risen in the past year.
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Life Sciences Tools & Services industry. The net income increased by 29.8% when compared to the same quarter one year prior, rising from $42.28 million to $54.86 million.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.